JP2021534094A5 - - Google Patents
Info
- Publication number
- JP2021534094A5 JP2021534094A5 JP2021506465A JP2021506465A JP2021534094A5 JP 2021534094 A5 JP2021534094 A5 JP 2021534094A5 JP 2021506465 A JP2021506465 A JP 2021506465A JP 2021506465 A JP2021506465 A JP 2021506465A JP 2021534094 A5 JP2021534094 A5 JP 2021534094A5
- Authority
- JP
- Japan
- Prior art keywords
- once
- alk
- weeks
- alk inhibitor
- administered
- Prior art date
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862715351P | 2018-08-07 | 2018-08-07 | |
| US62/715,351 | 2018-08-07 | ||
| US201862727056P | 2018-09-05 | 2018-09-05 | |
| US62/727,056 | 2018-09-05 | ||
| US201862748772P | 2018-10-22 | 2018-10-22 | |
| US62/748,772 | 2018-10-22 | ||
| US201862760529P | 2018-11-13 | 2018-11-13 | |
| US62/760,529 | 2018-11-13 | ||
| US201962822290P | 2019-03-22 | 2019-03-22 | |
| US62/822,290 | 2019-03-22 | ||
| PCT/IB2019/000905 WO2020030977A2 (en) | 2018-08-07 | 2019-08-07 | Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534094A JP2021534094A (ja) | 2021-12-09 |
| JPWO2020030977A5 JPWO2020030977A5 (https=) | 2022-08-12 |
| JP2021534094A5 true JP2021534094A5 (https=) | 2022-08-12 |
Family
ID=68425157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506465A Pending JP2021534094A (ja) | 2018-08-07 | 2019-08-07 | 未分化リンパ腫キナーゼ阻害剤と組み合わせてｅｇｆ／ｅｇｆｒ経路を抑制するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12257245B2 (https=) |
| EP (1) | EP3833384A2 (https=) |
| JP (1) | JP2021534094A (https=) |
| KR (1) | KR20210041571A (https=) |
| CN (1) | CN112996534B (https=) |
| AU (1) | AU2019319109A1 (https=) |
| BR (1) | BR112021002145A2 (https=) |
| CA (1) | CA3108236A1 (https=) |
| IL (1) | IL280632A (https=) |
| MX (1) | MX2021001398A (https=) |
| WO (1) | WO2020030977A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112300284B (zh) * | 2020-12-29 | 2021-04-06 | 慈达(广州)生物技术有限公司 | 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒 |
| WO2022256360A1 (en) * | 2021-06-02 | 2022-12-08 | Neuvogen, Inc. | Tumor cell vaccines |
| WO2023059801A1 (en) * | 2021-10-06 | 2023-04-13 | The Regents Of The University Of Colorado, A Body Corporate | Biomarkers for egfr-mediated resistance in oncogene-driven cancers and methods of treating, preventing, and/or ameliorating oncogene-driven cancers |
| KR102685187B1 (ko) | 2021-10-15 | 2024-07-16 | 제이투에이치바이오텍 (주) | Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 |
| MX2024005177A (es) * | 2021-10-28 | 2024-08-27 | In3Bio Ltd | Métodos de uso de anticuerpos anti-fce para aumentar la actividad de los inhibidores de braf y kras. |
| TW202339767A (zh) * | 2022-01-18 | 2023-10-16 | 大陸商齊魯製藥有限公司 | 螺環芳基磷氧化物與抗ｅｇｆｒ抗體的聯用藥物組合物及其用途 |
| WO2024017352A1 (zh) * | 2022-07-22 | 2024-01-25 | 四川大学 | 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒 |
| WO2024249331A1 (en) * | 2023-05-26 | 2024-12-05 | The Board Of Regents Of The University Of Texas System | Combined rtk and alk inhibition in rtk driven cancers |
| KR20250120789A (ko) | 2024-02-02 | 2025-08-11 | 제이투에이치바이오텍 (주) | E3 리가제 리간드 화합물, alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPH10147952A (ja) | 1996-11-18 | 1998-06-02 | Komatsu Ltd | ブルドーザのドージング装置 |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| AU2012312515A1 (en) * | 2011-09-19 | 2014-03-13 | Genentech, Inc. | Combination treatments comprising c-met antagonists and B-raf antagonists |
| JP6016953B2 (ja) | 2012-03-06 | 2016-10-26 | セファロン、インク． | 二重のａｌｋおよびｆａｋ阻害剤としての縮合二環式２，４−ジアミノピリミジン誘導体 |
| CA2882759C (en) * | 2012-08-31 | 2018-11-20 | The Regents Of The University Of Colorado | Detection of the ntrk1-mprip gene fusion for cancer diagnosis |
| WO2015148904A1 (en) * | 2014-03-28 | 2015-10-01 | Driver Group | Methods for predicting egfr tyrosine kinase inhibitor efficacy |
| KR102359214B1 (ko) * | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| US12595297B2 (en) | 2015-05-12 | 2026-04-07 | In3Bio Ltd. | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors |
| KR20180011839A (ko) * | 2015-06-08 | 2018-02-02 | 제넨테크, 인크. | 항-ox40 항체를 이용한 암의 치료 방법 |
| HK1251474A1 (zh) * | 2015-06-08 | 2019-02-01 | 豪夫迈‧罗氏有限公司 | 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法 |
| CN111246878A (zh) | 2017-07-18 | 2020-06-05 | 因斯瑞拜奥有限公司 | 合成蛋白及其治疗用途 |
| RU2654695C1 (ru) | 2017-07-28 | 2018-05-22 | Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") | 8-(1-{ 4-{ (5-Хлор-4-{ (2-(диметилфосфорил)фенил)амино} пиримидин-2-ил)амино)-3-метоксифенил} пиперидин-4-ил)-1-метил-1,8-диазаспиро(4.5)декан-2-он и его фармацевтически приемлемые соли в качестве модулятора ALK и EGER, предназначенные для лечения рака |
-
2019
- 2019-08-07 CN CN201980062030.6A patent/CN112996534B/zh active Active
- 2019-08-07 MX MX2021001398A patent/MX2021001398A/es unknown
- 2019-08-07 JP JP2021506465A patent/JP2021534094A/ja active Pending
- 2019-08-07 AU AU2019319109A patent/AU2019319109A1/en active Pending
- 2019-08-07 KR KR1020217004498A patent/KR20210041571A/ko active Pending
- 2019-08-07 US US16/534,230 patent/US12257245B2/en active Active
- 2019-08-07 EP EP19797349.8A patent/EP3833384A2/en active Pending
- 2019-08-07 WO PCT/IB2019/000905 patent/WO2020030977A2/en not_active Ceased
- 2019-08-07 CA CA3108236A patent/CA3108236A1/en active Pending
- 2019-08-07 BR BR112021002145A patent/BR112021002145A2/pt unknown
-
2021
- 2021-02-02 IL IL280632A patent/IL280632A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534094A5 (https=) | ||
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| US11932688B2 (en) | Treatment for neoplastic diseases | |
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| JP2018109022A5 (https=) | ||
| JP2019517549A5 (https=) | ||
| JP2008528486A5 (https=) | ||
| WO2020030977A3 (en) | Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors | |
| JPWO2022269525A5 (https=) | ||
| JP2009544610A5 (https=) | ||
| JPWO2020030977A5 (https=) | ||
| JP2021523096A5 (https=) | ||
| ES2991384T3 (es) | Composición farmacéutica, formulación farmacéutica combinada y kit de formulación combinada para la prevención o el tratamiento de la hepatitis B crónica, que comprende cada uno, como ingrediente activo, un agente antiviral oral y una vacuna terapéutica que incluye un lipopéptido y un adyuvante poli(I:C) | |
| RU2020134183A (ru) | Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы | |
| TW202535477A (zh) | 抗ｂ７ｈ３抗體—藥物偶聯物治療癌症的方法 | |
| TW202528000A (zh) | 人類表皮生長因子第二型受體疫苗組成物以及套組 | |
| RU2021105387A (ru) | Способы и композиции для подавления пути egf/egfr в комбинации с ингибиторами киназы анапластической лимфомы | |
| JPWO2022197900A5 (https=) | ||
| CN120202006A (zh) | 卡帕塞替尼和维奈托克的治疗组合 | |
| WO2013018018A1 (en) | Antitumour combination comprising ombrabulin and cetuximab, associated with radiotherapy | |
| HK40002544B (en) | Treatment for neoplastic diseases | |
| HK40002544A (en) | Treatment for neoplastic diseases | |
| Fotin-Mleczek et al. | 1253 POSTER Two-component Messenger RNA-based Vaccines Provide Strong Anti-tumoral Effect Especially in Combination With Radiation Therapy | |
| WO2013018017A1 (en) | Antitumour combination comprising ombrabulin and cisplatin, associated with radiotherapy | |
| HK1229696A1 (en) | Treatment for neoplastic diseases |